----
Current ValuationThe current P/E ratio is -1.10, above the reasonable range, cheaper than 3.7% of the time in the past 1 years, and the industry ranks 112/256, the industry Median -1.15.
-1.1xP/E
$1.68Stock price
$-1.52Earnings per share
-1.1xP/E
Stock price$1.68Earnings per share$-1.52
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -2.31x
- Typical range
- -2.61x–-1.72x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0306090120
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
TAKUSTakeda Pharmaceutical Company | -60.27x | 154.63% | $62.96B |
BAYRYUSBayer | -24.36x | -- | $49.08B |
BAYZFUSBayer Aktiengesellschaft | -24.08x | -- | $48.51B |
VTRSUSViatris | -51.60x | 107.68% | $21.19B |
ELANUSElanco Animal Health | -56.62x | 129.36% | $11.27B |
VREOFUSVIREO GROWTH INC | -126.10x | -- | $8.46B |
AXSMUSAxsome Therap | -42.72x | 21.41% | $8.19B |
CURLFUSCuraleaf Holdings, Inc. | -119.45x | -- | $6.21B |
BLTEUSBelite Bio | -60.26x | 29.87% | $6.17B |
MANEUSVeraDermics | -54.75x | 97.44% | $5.71B |
RGCUSRegencell Bioscience | -457.28x | -- | $5.35B |
DFTXUSDefinium Therapeutics | -13.48x | 54.55% | $4.77B |
EWTXUSEdgewise Therapeutics | -21.83x | 207.38% | $4.31B |
AMLXUSAmylyx Pharmaceuticals | -23.96x | 1.76% | $3.64B |
TARSUSTarsus Pharmaceuticals | -66.57x | 256.39% | $3.09B |
ELVNUSEnliven Therapeutics | -28.93x | 5.59% | $3.06B |
MBXUSMBX Biosciences | -24.90x | 31.12% | $2.60B |
BHCUSBausch Health | -2.20x | 569.84% | $2.41B |
SUPNUSSupernus Pharma | -21.80x | 66.18% | $2.40B |
PRGOUSPerrigo | -1.27x | 100.10% | $2.21B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
